# Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct07439211/  
OnCo record `nct07439211` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Eganelisib run by Jacqueline Garcia, MD, now recruiting.

## Summary

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia is a phase 1 interventional study registered as NCT07439211 by Jacqueline Garcia, MD, with 48 participants planned, started 2026-04-13. Conditions recorded: Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia and Refractory Leukemia. Interventions recorded: Eganelisib, Azacitidine and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07439211
- Phase: 1
- Setting: Safety of Targeting PI3Kgamma Signaling With Azacitidine, Venetoclax and Eganelisib in Acute Myeloid Leukemia: A Phase 1 Study (GAVEL)
- Sponsor: Jacqueline Garcia, MD
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07439211: https://clinicaltrials.gov/study/NCT07439211

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Eganelisib](https://onco.cc/drugs/eganelisib/)
- companies: [Stelexis BioSciences](https://onco.cc/companies/stelexis-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07439211.json